HIV Infection

Recent research in The Lancet HIV found that universal HIV screening for at-risk patients in a primary care setting is cost-effective.

In a recent study, researchers examined the costs of screening and evaluated the benefits and cost-effectiveness of screening for HIV in primary care.

All individuals diagnosed with HIV should be given the option to begin treatment with 7 days of diagnosis, according to new guidance from the World Health Organization issued on the opening day of the 9th...

An ongoing randomized clinical trial assessed the safety and efficacy of intramuscular long-acting HIV therapy compared with an oral therapy in adults with HIV.

The World Health Organization has released a warning of an increasing trend of resistance to widely used HIV drugs, based on data from national surveys conducted in several countries.

A recent study in the Journal of Managed Care Pharmacy examined the cost implications of switching first-line HIV treatment regimens.

Clinical guidelines vary for how often HIV-positive patients should be monitored, and several monitoring strategies exist. Researchers compared these strategies and their effects on patients in a recent...

Multiple phase 3 HIV trials suggest fixed-dose combination treatment regimens containing Gilead's investigational agent bictegravir are noninferior to those containing GlaxoSmithKline’s Tivicay.

A new study examines the possible impact of early ART exposure on renal and bone health in young adults with HIV.

After successful results from a pivotal clinical trial, a new dosage for an integrase inhibitor was approved by the FDA.